Affimed N.V.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Shawn Leland
- Full Time Employees
- 76
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Technologiepark Mannheim Germany 69120
- IPO Date
- Sep 12, 2014
- CIK
- 0001608390
- Website
- affimed.com
- Similar Companies
- Business
- Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies based in Heidelberg, Germany. The company develops a pipeline of innate cell engager (ICE) molecules designed to harness the body's immune system to fight cancer, including AFM13, a treatment in clinical trials for CD30-positive relapsed/refractory peripheral T-cell lymphoma and Hodgkin lymphoma; AFM24, a tetravalent bispecific innate cell engager in Phase IIa trials for advanced EGFR-expressing solid tumors; and preclinical candidates AFM28, AFM32, and AFM26 targeting various hematologic and solid tumor indications. Affimed operates strategic collaborations with companies such as Genentech for developing NK cell engager-based immunotherapies and Roivant Sciences Ltd. for oncology product commercialization. Founded in 2000, the company primarily serves patients in the United States and Europe. Recently, Affimed has announced advancement in clinical studies, including presentations of positive study results for acimtamig (AFM13) and AFM24 at the 2025 ASCO Annual Meeting, and granted orphan drug designation by the FDA for acimtamig. In 2025, Affimed filed for insolvency proceedings due to funding challenges and subsequently underwent a trading symbol change to AFMDQ on an OTC market in May 2025, reflecting significant operational restructuring. The company also secured $103.5 million in a public offering anchored by Gilde Healthcare and strengthened its pipeline and collaboration footprint despite recent financial difficulties.
Affimed Announces Receipt of Nasdaq Delisting Notice
Affimed Announces Filing for the Opening of Insolvency Proceedings
Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting
Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting
Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting
Affimed to Present at the Leerink Partners Global Healthcare Conference 2025
Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
AFMD Stock Down Despite FDA's RMAT Status for Lymphoma Therapy
Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)
Affimed N.V. (AFMD) Q3 2024 Earnings Call Transcript
Affimed Reports Third Quarter 2024 Financial Results & Business Update
Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024
Affimed to Present at the Cantor Global Healthcare Conference 2024
Affimed N.V. (AFMD) Q2 2024 Earnings Call Transcript
Affimed Reports Second Quarter 2024 Financial Results & Business Update
Affimed Follow Up: Upcoming Acimtamig And AFM24 Updates Could Be Positive Catalysts